https://www.selleckchem.com/pr....oducts/epacadostat-i
DR, and fatty liver did not decrease. When C-peptide is ≥ 1.71 and 2.51 ng/ml, patients with T2DM had a higher glycemic control rate. Excessive C-peptide plays different roles in DKD and DR; C-peptide may promote the incidence of DKD but protects patients from DR. Higher C2/C0 ratio is important for reaching glycaemic control but cannot reduce the risk of DKD, DR, and fatty liver. When C-peptide is ≥ 1.71 and less then 2.51 ng/ml, patients with T2DM had a higher glycemic control rate. Excessive C-peptide plays differ
Like
Comment
Share
